Valeant Pharmaceuticals
also referred to as: valeant
6 statements across 2 episodes · 0 bullish · 3 bearish · 2 people on the record · first statement Jun 9, 2020 by Bethany McLean · said 27 times in 2 episodes since 2020 · across every show →
Mentions by year
brought up most by Shane Parrish (27)
tap a year for its mentions
2025 7 mentions in 1 episode
2020 20 mentions in 1 episode
Everything said about Valeant Pharmaceuticals, oldest first
Jun 9, 2020 negative
McLean: Valeant pitched zero R&D and justified price hikes against liver transplants
“Their whole promise to investors was, we don't need to do R&D. So it wasn't an argument of, we're gonna take the profits we're making from this and invent new drugs that are gonna save people's lives or figure out a better drug to take, to treat this disease. …”
Jun 9, 2020
McLean: Companies that make enemies on the way up face vicious reversals
“But I think about this a lot, that if a company makes a lot of enemies as it's on its way up, you have to be a lot more skeptical about that company than about an average company, because when the tide turns, it's going to turn viciously.”
Jun 9, 2020 neutral
McLean: Unlike Enron, Valeant attracted smart money like Sequoia and Bill Ackman
“With Enron, when you got to what was commonly considered the smart money, people either weren't invested in Enron, or they were short. And it was largely long-only funds and index funds, and what we think of in terrible terms, but the dumb money that was inves…”
Jun 9, 2020 negative
McLean: Valeant's Pearson Weaponized 'Micro Truths' About Drug Profit Growth
“So Mike Pearson, right, had that argument, I'm gonna get it slightly wrong, but he said that most of Valiant's profit growth was not coming from increasing prices on drugs, it was coming from volume. And that turned out to be true if you looked at only their t…”
Jun 9, 2020 negative
McLean: Valeant's wrongdoing was drug price hikes, not hidden accounting
“The ways in which they were different, I don't think the substance of the Valiant story was accounting misrepresentation the way it was with Enron. You could actually see pretty clearly that what Valiant was doing with its numbers. There were a lot more of Enr…”